hey WSOers, just seeking some advice if there was an "updated" guide around the basic multiples and healthcare specific IB knowledge that would be helpful for interviews? Especially around biopharma and providers.
Any resources you all would recommend?
thank you
| +125 | UBS Americas IB: The Kids’ Table of Wall Street | 15 | 2d |
| +82 | Return Rates For Interns Are Falling? | 33 | 4h |
| +61 | London IB BB is a challenge | 38 | 8h |
| +54 | I am a drunk MD AMA | 29 | 5h |
| +53 | VP Lifestyle at Top BB Coverage Groups | 32 | 4h |
| +46 | SharePoint makes IB hours HELL | 15 | 1d |
| +46 | An Outsider’s View of RX Banking Out of College | 6 | 10h |
| +41 | momentum of Rx groups | 13 | 7h |
| +38 | Fired during interview | 7 | 10h |
| +29 | Most Technical Groups Ranked | 13 | 7h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Can you be more specific? When you say providers, I'm assuming you mean healthcare providers? Biopharma includes biotech, medical devices and pharma. These are basically three distinct fields. Even with pharma, you have generic, brand and specialty. There's also payers and wholesalers, each of which are distinct from biopharma and providers.
I can help with generic and brand pharma if you have targeted questions.
hey thank you. I just wanted to know how do they do valuations for biotech companies with no CFs? Also where can I find some uptodate multiples (What multiples are used for biotech comapnies and what do the ranges look like for say EV/EBITDA, etc...) thankyou
You could use forward multiples (ex. EV/peak sales)
They'll do a bottom-up, product level build-up for the the portfolio. If a company has a single product in development, pre-clinical for example, they'll estimate total targetable patient population, dose regimen, price per dose regimen, IP exclusivity period, length of approval and development period, COGS per dose (API + conversion cost) and then OPEX (distribution fees, sales and marketing expenses based on personal promotion required to drive uptake, manufacturing costs, regulatory and development costs, etc.). The uptake (how quickly the product acquires share) is usually based on analogs of similar products (same therapeutic area with aligned formulation and channel mix).
It's easy to run a DCF once you have the forecasts. In-development products are usually probability adjusted (cash flow weightings) to account for regulatory and technical uncertainty (non-market risk).
You can also value an early-stage, pre-revenue biotech company if they had a recent round of financing. It's a bit technical, but you model the cap structure and rights/preferences of each tranche and then "back solve" the implied price of the company based on the recent round of financing.
Very simple example: Company sells 1x share at $10. There are 100 shares, thus equity value is $1,000. Obviously, things get more complicated with participating/non-participating preferred, convertibles, options, warrants, etc.
Check Mergers and Inquisitions, always a good starting place, sell side handbook too
I remember there was a very good article about Healthcare group in IB where the guy talked about the differences of Healthcare with the other industries, look at past posts and you will find it!
https://www.wallstreetoasis.com/forums/biotech-finance-from-ib-to-vc-hf…
here is the link
Molestiae aspernatur voluptatem aut ut odit quibusdam ut. Vero officia distinctio vero exercitationem accusantium omnis. Odit voluptatem voluptate omnis vero. Veniam nesciunt in totam ut in.
Quisquam qui maxime odio fugit enim nulla rerum. Saepe sed beatae est quasi beatae. Sunt veniam sint similique temporibus labore a facilis.
Voluptatem corporis eligendi est ducimus. Doloremque quasi repellat facere aut. Maxime assumenda perferendis nemo voluptas. Adipisci quam beatae exercitationem enim dolore.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...